Johnson & Johnson announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of nipocalimab, a fully human FcRn-blocking monoclonal antibody, as an add-on to standard therapy for the treatment of generalized myasthenia gravis. “The recommendation is for nipocalimab in a broad population of people living with gMG including adults and adolescent patients 12 years of age and older who are anti-acetylcholine receptor or anti-muscle-specific kinase antibody positive,” the company said in a statement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- JNJ: TECVAYLI/DARZALEX FASPRO regimen shows positive results in study
- How Johnson & Johnson Stock (JNJ) Became a Bargain Again
- Nanobiotix announces new results from JNJ-1900 study
- Johnson & Johnson reports data from Phase 3 Iconic-Advance studies
- Citizens JMP healthcare analysts hold an analyst/industry conference call